A Phase 3 interventional study of gadopiclenol and Gadobutrol 1 MMOLE/ML Intravenous Solution in Lesion in Body Region, sponsored by Guerbet. Completed at 33 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-27.
Sponsored by Guerbet · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The trial aimed at evaluating the efficacy and the safety of gadopiclenol for body Magnetic resonance Imaging (MRI)
The purpose of this trial was to evaluate a new gadolinium-based contrast agent (GBCA) gadopiclenol in terms of lesion visualization in patients referred for contrast-enhanced MRI of body regions.
This is a prospective, international, multi-center, randomized, double-blind, controlled and cross-over trial.
This trial was conducted in 33 centers worldwide. During the course of the trial, two MRIs were obtained from each patient: one with gadopiclenol and one with gadobutrol. MRI evaluations were assessed by independent off-site blinded readers.
Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cross-over design: each patient receives gadopiclenol for the first MRI and then gadobutrol for the second MRI
Drug: gadopiclenol · Drug: Gadobutrol 1 MMOLE/ML Intravenous Solution
Cross-over design: each patient receives gadobutrol for the first MRI and then gadopiclenol for the second MRI
Drug: gadopiclenol · Drug: Gadobutrol 1 MMOLE/ML Intravenous Solution
Single intravenous bolus injection
Single intravenous bolus injection
Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Unenhanced MRI
The lesion visualization at patient level was based on 3 co-primary criteria on marching lesions: border delineation, internal morphology and degree of contrast enhancement, assessed on the images acquired during the MRI performed with gadopiclenol by 3 independent readers. The independent blinded reader recorded each of the 3 co-primary criteria for up to 3 most representative lesions, using a 4-point scale (1 = poor \[internal morphology\] or none \[border delineation, contrast enhancement\], 2 = moderate, 3 = good, 4 = excellent). The mean of scores for each patient and for each co-criterion was calculated as follows: Mean of scores = score of lesion 1 + score of lesion 2 (if any) + score of lesion 3 (if any) divided by the number of lesions, ranged from 1 to 4. The difference in mean scores on matching lesions between Paired \[unenhanced and contrast-enhanced\] images and Pre-contrast \[unenhanced\] images was calculated for each of the 3 co-primary criteria and for each reader.
Time frame: At first MRI examination (gadopiclenol-enhanced MRI) for patients of Arm 1. At second MRI examination (gadopiclenol-enhanced MRI) for patients of Arm 2, performed 2-14 days after gadobutrol-enhanced MRI.
Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Gadobutrol-enhanced MRI
The lesion visualization (per patient) was based on 3 co-primary criteria: border delineation, internal morphology and degree of contrast enhancement, assessed on the images performed with gadopiclenol and images performed with gadobutrol by 3 independent readers. The independent blinded reader recorded each of the 3 co-primary criteria for up to 3 most representative lesions, using a 4-point scale (1 = poor \[internal morphology\] or none \[border delineation, contrast enhancement\], 2 = moderate, 3 = good, 4 = excellent). The mean of scores for each patient and for each of the 3 lesion visualization co-criteria was calculated as follows: Mean of scores = score of lesion 1 + score of lesion 2 (if any) + score of lesion 3 (if any) divided by the number of lesions, ranged from 1 to 4. The difference in mean scores on matching lesions between gadopiclenol scores mean and gadobutrol scores mean was calculated for each of the 3 co-primary criteria and for each reader.
Time frame: At each of two MRI examinations with an interval of 2-14 days between two MRI examinations
| Milestone | Arm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRI | Arm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRI |
|---|---|---|
| Started | 152 | 152 |
| Completed | 151 | 149 |
| Not completed | 1 | 3 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Other reason (mainly technical issues with mri machine) | 1 | 2 |
| Milestone | Arm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRI | Arm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRI |
|---|---|---|
| Started | 151 | 149 |
| Completed | 141 | 136 |
| Not completed | 10 | 13 |
| Withdrew: Withdrawal by subject | 4 | 5 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Other reason | 5 | 5 |
| Milestone | Arm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRI | Arm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRI |
|---|---|---|
| Started | 141 | 136 |
| Completed | 141 | 134 |
| Not completed | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 2 |
The lesion visualization at patient level was based on 3 co-primary criteria on marching lesions: border delineation, internal morphology and degree of contrast enhancement, assessed on the images acquired during the MRI performed with gadopiclenol by 3 independent readers. The independent blinded reader recorded each of the 3 co-primary criteria for up to 3 most representative lesions, using a 4-point scale (1 = poor \[internal morphology\] or none \[border delineation, contrast enhancement\], 2 = moderate, 3 = good, 4 = excellent). The mean of scores for each patient and for each co-criterion was calculated as follows: Mean of scores = score of lesion 1 + score of lesion 2 (if any) + score of lesion 3 (if any) divided by the number of lesions, ranged from 1 to 4. The difference in mean scores on matching lesions between Paired \[unenhanced and contrast-enhanced\] images and Pre-contrast \[unenhanced\] images was calculated for each of the 3 co-primary criteria and for each reader.
| mean of a score (on a scale) per patient | Patients With Gadopiclenol Paired Images | Patients With Gadopiclenol Pre Images |
|---|---|---|
| Border delineation - Reader 1 | 3.79 ± 0.03 | 2.26 ± 0.03 |
| Border delineation - Reader 2 | 3.48 ± 0.06 | 3.01 ± 0.06 |
| Border delineation - Reader 3 | 3.49 ± 0.03 | 1.78 ± 0.03 |
| Internal morphology - Reader 1 | 3.80 ± 0.02 | 1.99 ± 0.02 |
| Internal morphology - Reader 2 | 3.75 ± 0.05 | 3.22 ± 0.05 |
| Internal morphology - Reader 3 | 3.72 ± 0.03 | 1.69 ± 0.03 |
| Contrast enhancement - Reader 1 | 3.64 ± 0.03 | 1.00 ± 0.03 |
| Contrast enhancement - Reader 2 | 2.82 ± 0.05 | 1.00 ± 0.05 |
| Contrast enhancement - Reader 3 | 3.33 ± 0.03 | 1.00 ± 0.03 |
The lesion visualization (per patient) was based on 3 co-primary criteria: border delineation, internal morphology and degree of contrast enhancement, assessed on the images performed with gadopiclenol and images performed with gadobutrol by 3 independent readers. The independent blinded reader recorded each of the 3 co-primary criteria for up to 3 most representative lesions, using a 4-point scale (1 = poor \[internal morphology\] or none \[border delineation, contrast enhancement\], 2 = moderate, 3 = good, 4 = excellent). The mean of scores for each patient and for each of the 3 lesion visualization co-criteria was calculated as follows: Mean of scores = score of lesion 1 + score of lesion 2 (if any) + score of lesion 3 (if any) divided by the number of lesions, ranged from 1 to 4. The difference in mean scores on matching lesions between gadopiclenol scores mean and gadobutrol scores mean was calculated for each of the 3 co-primary criteria and for each reader.
| mean of a score (on a scale) per patient | Patients With Gadopiclenol Paired Images | Patients With Gadobutrol Paired Images |
|---|---|---|
| Border delineation - Reader 1 | 3.82 ± 0.02 | 3.81 ± 0.02 |
| Border delineation - Reader 2 | 3.56 ± 0.05 | 3.53 ± 0.05 |
| Border delineation - Reader 3 | 3.53 ± 0.03 | 3.57 ± 0.03 |
| Internal morphology - Reader 1 | 3.83 ± 0.02 | 3.83 ± 0.02 |
| Internal morphology - Reader 2 | 3.75 ± 0.04 | 3.75 ± 0.04 |
| Internal morphology - Reader 3 | 3.74 ± 0.03 | 3.77 ± 0.03 |
| Contrast enhancement - Reader 1 | 3.69 ± 0.04 | 3.68 ± 0.04 |
| Contrast enhancement - Reader 2 | 2.88 ± 0.07 | 2.86 ± 0.07 |
| Contrast enhancement - Reader 3 | 3.35 ± 0.04 | 3.37 ± 0.04 |
Collected over Adverse events were recorded from informed consent signature up to one day after the second MRI (i.e., minimum of 4 days and a maximum of 23 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gadopiclenol | 0/288 (0%) | 3/288 (1%) | 50/288 (17.4%) |
| Gadobutrol | 0/290 (0%) | 0/290 (0%) | 58/290 (20%) |
| Event | Gadopiclenol | Gadobutrol |
|---|---|---|
| Condition AggravatedGeneral disorders | 1/288 | 0/290 |
| Depressed Level Of ConsciousnessNervous system disorders | 1/288 | 0/290 |
| Covid-19Infections and infestations | 1/288 | 0/290 |
| Event | Gadopiclenol | Gadobutrol |
|---|---|---|
| HeadacheNervous system disorders | 16/288 | 4/290 |
| Injection site painGeneral disorders | 5/288 | 7/290 |
| NauseaGastrointestinal disorders | 5/288 | 4/290 |
| Incorrect dosage administeredInjury, poisoning and procedural complications | 5/288 | 4/290 |
| NeutropeniaBlood and lymphatic system disorders | 1/288 | 4/290 |
| Injection site bruisingGeneral disorders | 3/288 | 1/290 |
| Dry mouthGastrointestinal disorders | 3/288 | 3/290 |
| AnaemiaBlood and lymphatic system disorders | 2/288 | 3/290 |
| LeukopeniaBlood and lymphatic system disorders | 0/288 | 3/290 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/288 | 3/290 |
The analysis was based on participants. For the primary analysis to demonstrate the superiority of gadopiclenol-enhanced MRI compared to unenhanced MRI, the analysis population was patients who had both Pre (unenhanced) and Paired (combined unenhanced and contrast-enhanced) images with gadopiclenol assessable for primary criteria for at least one matching lesion for at least one off-site reader: 145 patients of Arm 1 who performed first MRI and 133 patients of Arm 2 who performed second MRI.
| Age, Continuous(years) | Arm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRI | Arm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRI | Total |
|---|---|---|---|
| Mean | 57.5 ± 12.9 | 56.9 ± 13.1 | 57.2 ± 13.0 |
| Sex: Female, Male(Participants) | Arm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRI | Arm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRI | Total |
|---|---|---|---|
| Female | 82 | 82 | 164 |
| Male | 63 | 51 | 114 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRI | Arm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRI | Total |
|---|---|---|---|
| Hispanic or Latino | 31 | 20 | 51 |
| Not Hispanic or Latino | 114 | 113 | 227 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Arm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRI | Arm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRI | Total |
|---|---|---|---|
| American Indian or Alaska Native | 18 | 12 | 30 |
| Asian | 22 | 22 | 44 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 4 | 6 |
| White | 102 | 94 | 196 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Arm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRI | Arm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRI | Total |
|---|---|---|---|
| South Korea | 22 | 22 | 44 |
| Hungary | 28 | 20 | 48 |
| United States | 27 | 18 | 45 |
| Ukraine | 4 | 9 | 13 |
| Poland | 32 | 35 | 67 |
| Italy | 0 | 1 | 1 |
| Mexico | 18 | 12 | 30 |
| France | 8 | 2 | 10 |
| Bulgaria | 2 | 9 | 11 |
| Germany | 2 | 3 | 5 |
| Spain | 2 | 2 | 4 |
| Weight(Kg) | Arm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRI | Arm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRI | Total |
|---|---|---|---|
| Mean | 75.3 ± 17.1 | 75.5 ± 17.1 | 75.4 ± 17.1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2019 to primary completion in Dec 2020, 15 months.
Results were first posted in Oct 2025, 4 years 10 months after primary completion. A results delay was requested in May 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gadopiclenol